The two loans have an initial term of one year with a five-year extension option. They are 90% guaranteed by the French state as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic.
'This additional financing provides the opportunity to further strengthen our cash position as well as our research and development activities in
About
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including
Headquartered in
Euronext Paris and Nasdaq in the US.
Learn more about
Information about
ISIN code Ticker code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including 'believe,' 'potential,' 'expect' and 'will' and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-
19 outbreak on the global healthcare system as well as the Company's business, financial condition and results of operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking statements, please refer to
the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document filed
with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
Contact:
Investors
Tel: +33 761 88 38 74
E: Henry.wheeler@innate-pharma.fr
Media
Global/US
Tel: +1 240 801 0076
E: Tracy.Rossin@innate-pharma.com
Marie Puvieux
Tel: +33 (0)9 81 87 46 72
E: innate-pharma@atcg-partners.com
(C) 2022 Electronic News Publishing, source